Analysis Tools
hematopoietic system
|
• in lethally irradiated host when transplanted with bone marrow cells
|
|
• decreased number and increased fraction of apoptotic common myeloid progenitors granulocyte-monocyte progenitors and megakaryocyte-erythroid progenitors following pIpC treatment
|
|
• decreased myeloid cells in bone marrow and spleen at 21 days post pIpC treatment every other day for 5 days
• impact on myeloid compartment is more profound than B and T cell compartments
|
|
• at 21 days post pIpC treatment every other day for 5 days
|
|
• decreased in number and increased fraction of apoptotic in pIpC-treated mice
|
|
• at 21 days post pIpC treatment every other day for 5 days
|
|
• in peripheral blood following pIpC treatment
|
|
• in peripheral blood following pIpC treatment
|
|
• in peripheral blood following pIpC treatment
|
|
• in peripheral blood but not significantly depleted in the thymus
|
|
• in bone marrow and spleen at 21 days post pIpC treatment every other day for 5 days
|
|
• decrease in the number of T-lineage (CD3+) cells in bone marrow and spleen at 21 days post pIpC treatment every other day for 5 days
|
|
• following pIpC treatment
• decreased total number of multipotent progenitors following pIpC treatment
• percentage of cell death of hematopoietic stem cells and multipotent progenitors are similar to control
|
|
• at 21 days post pIpC treatment every other day for 5 days
|
immune system
|
• decreased myeloid cells in bone marrow and spleen at 21 days post pIpC treatment every other day for 5 days
• impact on myeloid compartment is more profound than B and T cell compartments
|
|
• in peripheral blood following pIpC treatment
|
|
• in peripheral blood following pIpC treatment
|
|
• in peripheral blood but not significantly depleted in the thymus
|
|
• in bone marrow and spleen at 21 days post pIpC treatment every other day for 5 days
|
|
• decrease in the number of T-lineage (CD3+) cells in bone marrow and spleen at 21 days post pIpC treatment every other day for 5 days
|
|
• at 21 days post pIpC treatment every other day for 5 days
|
cellular
|
• significantly increased fraction of cells in S and G2/M phases in bone marrow cells of 2 hours post pIpC-treated animals, with lesser increase in the myeloid progenitors
|
|
• in lethally irradiated host when transplanted with bone marrow cells
|
